An observational study in Atrial Fibrillation, Frailty and Major Bleed, sponsored by Dijklander Ziekenhuis. Active, not recruiting at 6 sites in Netherlands. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-02-20.
Sponsored by Dijklander Ziekenhuis · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 255 studies in Atrial Fibrillation with a site in Netherlands — 33 open to participants now, 49 under way, 2 of them phase 3. Atrial Fibrillation · Netherlands.
Among the 255 studies in Atrial Fibrillation with a site in Netherlands, this one is the 21st largest by enrollment of the 63 observational ones that give a count, is one of 11 that started in 2021, is one of 63 observational ones, reaches primary completion later than 0 of the 48 other live ones, and was the 195th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →33 of the 255 studies in Atrial Fibrillation with a site in Netherlands are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Netherlands, Belgium, Germany and 3 more countries
Ages 18+
Bayer · Sites in Netherlands, United States, Belgium and 5 more countries
Ages 18–85
Milestone Pharmaceuticals Inc. · Sites in Netherlands, United States, Canada
Ages 18+
Happitech BV · Sites in Netherlands, United States
Ages 22 min+
Novartis Pharmaceuticals · Sites in Netherlands, United States, Canada and 4 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
255 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 23 · Phase 3 33 · Phase 4 29
First in 2000; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,075 is above the median of 300 across 1,401 observational studies indexed under Atrial Fibrillation.
Median enrollment 250 across the 192 interventional studies, 400 across the 63 observational. Of the 185 that completed or were terminated, 72 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
135 of 255 have an industry lead sponsor. The 10 most frequent:
Dijklander Ziekenhuis is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Dijklander Ziekenhuis has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
13 of the studies in Atrial Fibrillation with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07779213Happitech BVDetection of Atrial Fibrillation Using PPG From Smartphone Cameras | 2026-11 |
| NCT06355063Pulse Biosciences, Inc.CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation | 2026-12-31 |
| NCT06106594Abbott Medical DevicesVOLT CE Mark Study | 2027-01 |
| NCT06808217Boston Scientific CorporationA Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation | 2027-04-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 255 studies in Atrial Fibrillation with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Geriatric patients are at high risk of cardiovascular complications, and for the development of atrial fibrillation. Often atrial fibrillation exists in these patients without specific symptoms, and could therefore remain unknown. Furthermore, concerns exist about the bleeding profile of anticoagulation in the very elderly or frail patients.
This study applies opportunistic screening for atrial fibrillation as advised in the latest ESC Guideline on the diagnosis and management of atrial fibrillation. Furthermore, multiple bleeding risk scores will be applies, to better assess the bleeding risk in very elderly or frail patients.
All newly referred patients of 65 years and older that visit a geriatric outpatient service. These will form a cohort of very elderly individuals, with multi morbidity, polypharmacy, cognitive disorders, high frailty and high risk for falling. They can also be seen as a group at high risk of cardiovascular complication and/or the development of cognitive disorders.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All newly referred patients of 65 years and older that visit geriatric outpatient services are eligible (including Fall clinic, Memory clinic, Pre-operative geriatric assessment clinic, or any other geriatric outpatient clinics that are led by a geriatrician).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The photoplethysmography (PPG) application enables patients to perform a finger tip heartbeat measurement and automatic analysis
Newly identified cases of atrial fibrillation
PPG or ECG detected new cases of atrial fibrillation
Time frame: The first 6 months after recruitment for the study
Major bleeding
Major bleeding, including intra cranial haemorrhage
Time frame: From recruitment until 3 years after the recruitment of the last participant
Stroke
Stroke
Time frame: From recruitment until 3 years after the recruitment of the last participant
Death
Death
Time frame: From recruitment until 3 years after the recruitment of the last participant
Cognitive disorder
Development of dementia, categorized by aetiology, during follow up
Time frame: From recruitment until 3 years after the recruitment of the last participant
New Atrial Fibrillation, developed after the screening period
New Atrial Fibrillation, developed after the screening period
Time frame: From recruitment until 3 years after the recruitment of the last participant
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Upon reasonable request, anonymized data could be shared after approval of all principal investigators
Ran from Jan 2021 to primary completion in Oct 2022, 21 months.
Of 551 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's 21 months is below that.
Counting every sponsor, half of 699 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dijklander Ziekenhuis